Patents Assigned to Xencor, Inc.
  • Antibodies That Specifically Bind to DR3
    Publication number: 20120014950
    Abstract: The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Application
    Filed: August 24, 2011
    Publication date: January 19, 2012
    Applicants: Xencor, Inc., Human Genome Sciences, Inc.
    Inventors: Thi-Sau Migone, Chih-Hung Lo, Luke Oh, Heather Wasserman, Madhav Devalaraja, Matthew J. Bernett
  • Optimized Anti-CD30 Antibodies
    Publication number: 20120014943
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-Iu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Optimized Fc variants and methods for their generation
    Patent number: 8093359
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: January 10, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 8093357
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: January 10, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen Kohl Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8088376
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: January 3, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized anti-CD20 monoclonal antibodies having Fc variants
    Patent number: 8084582
    Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: December 27, 2011
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory Alan Lazar, Omid Vafa
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20110287032
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: February 22, 2011
    Publication date: November 24, 2011
    Applicant: XENCOR, INC.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 8063187
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 22, 2011
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Optimized Fc variants and methods for their generation
    Patent number: 8039592
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 18, 2011
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Fc Variants with Optimized Properties
    Publication number: 20110250681
    Abstract: The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.
    Type: Application
    Filed: May 6, 2011
    Publication date: October 13, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki
  • METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING CONTENT AND COMPOSITIONS THEREOF
    Publication number: 20110236969
    Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
    Type: Application
    Filed: March 21, 2011
    Publication date: September 29, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
  • ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY
    Publication number: 20110236375
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Application
    Filed: January 19, 2011
    Publication date: September 29, 2011
    Applicant: XENCOR, INC.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20110189178
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Applicant: XENCOR, INC.
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • Optimized anti-CD30 antibodies
    Patent number: 7973136
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 5, 2011
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • FC VARIANTS WITH ALTERED BINDING TO FCRN
    Publication number: 20110110928
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Application
    Filed: January 18, 2011
    Publication date: May 12, 2011
    Applicant: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Methods of generating variant proteins with increased host string content
    Patent number: 7930107
    Abstract: The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 19, 2011
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond
  • Immunoglobulin Variants Outside the Fc Region
    Publication number: 20110064727
    Abstract: The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application.
    Type: Application
    Filed: August 20, 2007
    Publication date: March 17, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Sher Bahadur Karki
  • COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
    Publication number: 20110054151
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 3, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Gregory L. Moore
  • Optimized CD40 Antibodies and Methods of Using the Same
    Publication number: 20110027276
    Abstract: The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Application
    Filed: January 21, 2009
    Publication date: February 3, 2011
    Applicant: Xencor ,Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, Eugene Alexande Zhukovsky
  • Optimized Fc Variants
    Publication number: 20110021755
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 27, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter